Fujisawa's Antifungal Mycamine Clears FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The product will be rolled out by the summer, with detailing by Fujisawa's existing immunology and hospital sales forces. Micafungin is approved for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation and treatment of esophageal candidiasis.